Disposition of 1291 shares by Henderson Molly of Phathom Pharmaceuticals at 8.0 subject to Rule 16b-3
| PHAT Stock | USD 5.99 0.35 5.52% |
Slightly above 62% of Phathom Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Phathom Pharmaceuticals stock suggests that many investors are alarmed at this time. Phathom Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Phathom Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Phathom |
Filed transaction by Phathom Pharmaceuticals Officer: Cfo And Cbo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Phathom Pharmaceuticals Fundamental Analysis
We analyze Phathom Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Phathom Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Phathom Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Phathom Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Phathom Pharmaceuticals Related Equities
| XFOR | X4 Pharmaceuticals | 6.06 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.99 | ||||
| GPCR | Structure Therapeutics | 1.15 | ||||
| BPMC | Blueprint Medicines | 1.33 | ||||
| INZY | Inozyme Pharma | 1.37 | ||||
| IMMX | Immix Biopharma | 1.52 | ||||
| KNSA | Kiniksa Pharmaceuticals | 3.78 | ||||
| DAWN | Day One | 3.81 | ||||
| CGEM | Cullinan Oncology | 3.83 | ||||
| ABOS | Acumen Pharmaceuticals | 3.85 | ||||
| TERN | Terns Pharmaceuticals | 3.88 | ||||
| LYRA | Lyra Therapeutics | 5.26 | ||||
| HEPA | Hepion Pharmaceuticals | 5.26 |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.